Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Genius, a "stock dividend" is a dividend of stock - not cash.
Actually, footnote 2 to the 10-Q (at page 12) clearly identifies the remaining one-time milestone as "drafting key portions of the application for product approval."
06/06/2023 108 LETTER addressed to Magistrate Judge Gabriel W. Gorenstein from William A. Burck dated June 6, 2023 re: extension of the briefing deadlines for Defendants' motion to dismiss. Document filed by Canaccord Genuity LLC, Citadel Securities LLC, G1 Execution Services LLC, GTS Securities LLC, Instinet LLC, Lime Trading Corp., Virtu Americas LLC..(Burck, William) (Entered: 06/06/2023)
06/06/2023 109 MEMO ENDORSEMENT: on re: 108 Letter filed by G1 Execution Services LLC, Lime Trading Corp., Virtu Americas LLC, GTS Securities LLC, Citadel Securities LLC, Canaccord Genuity LLC, Instinet LLC. ENDORSEMENT: The proposed revision to the briefing schedule is approved. SO ORDERED., ( Motions due by 7/12/2023., Responses due by 8/25/2023, Replies due by 9/27/2023.) (Signed by Magistrate Judge Gabriel W. Gorenstein on 6/06/2023) (ama) (Entered: 06/06/2023)
UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK
---------------------------------------------------------------X
NORTHWEST BIOTHERAPEUTICS, INC., :
Plaintiff, : ORDER
-v.- :
22 Civ. 10185 (GHW) (GWG)
CANACCORD GENUITY LLC et al.,, :
Defendants. :
---------------------------------------------------------------X
GABRIEL W. GORENSTEIN, UNITED STATES MAGISTRATE JUDGE
The Court is in receipt of a letter from plaintiff (Docket # 102) submitting a corrected Exhibit 1
(Docket # 102-1) meant to substitute for the Exhibit 1 to the First Amended Complaint (Docket # 95-1).
We have considered the defendants’ opposition. See Docket ## 103 & 104. Because the errors to the
original Exhibit 1 were due only to a “ministerial transcription error caused in converting an Excel file
into a Word file for filing” (Docket # 105 at 1), because there has been no suggestion of any prejudice
from the amendment (other than the need to file a motion to dismiss, whose deadline the Court will
extend should the defendants request it), and because Fed. R. Civ. P. 15 requires that leave to amend be
“freely give[n],” the revised Exhibit 1 (Docket # 102-1) is deemed to replace the current Exhibit 1
(Docket # 95-1).
SO ORDERED.
Dated: May 31, 2023
It appears from the original Complaint that Susquehanna was sued based on the conduct of G1 Execution Services LLC, which is alleged to have been purchased by Susquehanna in 2014. Plaintiff's lawyers likely do not have evidence of spoofing by Susquehanna other than through G1, so Susquehanna was dropped as a defendant.
Ignore it then. Although it appears that each of the listed individuals is indicated as an "author" of the Abstract to be presented by Dr. Liau.
A view of the data from the SNO web page shows the following hidden data related to Dr. Liau's presentation.
<div class="clear"></div>
<i class="hidden"> Linda M. Liau, MD PhD (she/her/hers) – University of California, Los Angeles ### 610625###Plenary Abstract Presenter###Department of Neurosurgery Chair###University of California, Los Angeles###<p style='margin-bottom:5px;'>Plenary Abstract Presenter: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=610625 href=javascript: void(0);>Linda M. Liau, MD PhD (she/her/hers)</span> – University of California, Los Angeles</p> ### she/her/hers @@@ Keyoumars Ashkan – King's College Hospital ### 613608###Author######King's College Hospital###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=613608 href=javascript: void(0);>Keyoumars Ashkan</span> – King's College Hospital</p> ### @@@ Steven Brem, MD – Hospital of the University of Pennsylvania ### 1060314###Author###Professor of Neurosurgery at the Hospital of the University of Pennsylvania###Hospital of the University of Pennsylvania###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1060314 href=javascript: void(0);>Steven Brem, MD</span> – Hospital of the University of Pennsylvania</p> ### @@@ Jian L. Campian, MD, PhD – Mayo Clinic, Department of Oncology ### 1711821###Author###Associate Professor of Oncology###Mayo Clinic, Department of Oncology###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1711821 href=javascript: void(0);>Jian L. Campian, MD, PhD</span> – Mayo Clinic, Department of Oncology</p> ### @@@ John Trusheim, MD – Abbott Northwestern Hospital ### 613426###Author###l; Medical Director of Neuro-Oncology at the Virginia Piper Cancer Institute; Medical Director of th###Abbott Northwestern Hospital###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=613426 href=javascript: void(0);>John Trusheim, MD</span> – Abbott Northwestern Hospital</p> ### @@@ Fabio Iwamoto – Columbia University Medical Center ### 1713078###Author######Columbia University Medical Center###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1713078 href=javascript: void(0);>Fabio Iwamoto</span> – Columbia University Medical Center</p> ### @@@ David D. Tran, MD, PhD – University of Southern California ### 612000###Author###Professor of Neurosurgery and Neurology, Chief of Neuro-Oncology, Co-Director, USC Brain Tumor Center,###University of Southern California###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=612000 href=javascript: void(0);>David D. Tran, MD, PhD</span> – University of Southern California</p> ### @@@ George Anstass, MD – Washington University ### 818178###Author###Associate Professor###Washington University###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=818178 href=javascript: void(0);>George Anstass, MD</span> – Washington University</p> ### @@@ Charles Cobbs – Swedish Hospital ### 819926###Author######Swedish Hospital###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=819926 href=javascript: void(0);>Charles Cobbs</span> – Swedish Hospital</p> ### @@@ Jason Heth – University of Michigan ### 611924###Author######University of Michigan###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=611924 href=javascript: void(0);>Jason Heth</span> – University of Michigan</p> ### @@@ Michael E. Salacz, MD – Rutgers University ### 1379709###Author###Director, Neuro-Oncology Program###Rutgers University###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1379709 href=javascript: void(0);>Michael E. Salacz, MD</span> – Rutgers University</p> ### @@@ Stacy D'Andre – Mayo Clinic ### 1713367###Author######Mayo Clinic###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1713367 href=javascript: void(0);>Stacy D'Andre</span> – Mayo Clinic</p> ### @@@ Robert Aiken, MD – Rutgers ### 611253###Author######Rutgers###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=611253 href=javascript: void(0);>Robert Aiken, MD</span> – Rutgers</p> ### @@@ Yaron Moshel – Atlantic Healthcare ### 864370###Author######Atlantic Healthcare###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=864370 href=javascript: void(0);>Yaron Moshel</span> – Atlantic Healthcare</p> ### @@@ JooYeon Nam – Rush Medical College ### 614229###Author######Rush Medical College###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=614229 href=javascript: void(0);>JooYeon Nam</span> – Rush Medical College</p> ### @@@ Clement Pillainayagam – The Ohio State University ### 1713381###Author######The Ohio State University###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1713381 href=javascript: void(0);>Clement Pillainayagam</span> – The Ohio State University</p> ### @@@ Stephanie Wagner – Columbus Regional Health ### 1713383###Author######Columbus Regional Health###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1713383 href=javascript: void(0);>Stephanie Wagner</span> – Columbus Regional Health</p> ### @@@ Kevin A. Walter – University of Rochester ### 613931###Author######University of Rochester###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=613931 href=javascript: void(0);>Kevin A. Walter</span> – University of Rochester</p> ### @@@ Rekha Chaudary – University of Cincinnati ### 614933###Author######University of Cincinnati###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=614933 href=javascript: void(0);>Rekha Chaudary</span> – University of Cincinnati</p> ### @@@ Samuel A. Goldlust, MD – Hackensack University ### 614934###Author###Pitkin Endowed Chair in Neuro-Oncology###Hackensack University###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=614934 href=javascript: void(0);>Samuel A. Goldlust, MD</span> – Hackensack University</p> ### @@@ Ian Y. Lee, MD – Henry Ford Health ### 611566###Author###Neurosurgeon###Henry Ford Health###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=611566 href=javascript: void(0);>Ian Y. Lee, MD</span> – Henry Ford Health</p> ### @@@ Daniela A. Bota, MD, PhD – University of California Irvine ### 611432###Author###Professor###University of California Irvine###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=611432 href=javascript: void(0);>Daniela A. Bota, MD, PhD</span> – University of California Irvine</p> ### @@@ Heinrich Elinzano, MD – Rhode Island Hospital ### 1058150###Author###Physician###Rhode Island Hospital###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1058150 href=javascript: void(0);>Heinrich Elinzano, MD</span> – Rhode Island Hospital</p> ### @@@ Jai Grewal, MD – Mount Sinai South Nassau Hospital, Oceanside, NY ### 1711900###Author######Mount Sinai South Nassau Hospital, Oceanside, NY###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1711900 href=javascript: void(0);>Jai Grewal, MD</span> – Mount Sinai South Nassau Hospital, Oceanside, NY</p> ### @@@ Kevin Lillehei – University of Colorado ### 816456###Author######University of Colorado###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=816456 href=javascript: void(0);>Kevin Lillehei</span> – University of Colorado</p> ### @@@ Tom Mikkelsen, MD – Henry Ford Health System ### 611290###Author######Henry Ford Health System###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=611290 href=javascript: void(0);>Tom Mikkelsen, MD</span> – Henry Ford Health System</p> ### @@@ Tobias Walbert, MD, PhD. – Henry Ford Health ### 610400###Author###Senior Staff Neuro-Oncologist, Director of The Hermelin Brain Tumor Center,###Henry Ford Health###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=610400 href=javascript: void(0);>Tobias Walbert, MD, PhD.</span> – Henry Ford Health</p> ### @@@ Steve R. Abram, MD – St. Thomas Hospital ### 1057312###Author######St. Thomas Hospital###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1057312 href=javascript: void(0);>Steve R. Abram, MD</span> – St. Thomas Hospital</p> ### @@@ Andrew J. Brenner, MD.,Ph.D – UT Health San Antonio ### 611077###Author###Professor###UT Health San Antonio###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=611077 href=javascript: void(0);>Andrew J. Brenner, MD.,Ph.D</span> – UT Health San Antonio</p> ### @@@ Matthew Ewend – University of North Carolina ### 1713414###Author######University of North Carolina###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1713414 href=javascript: void(0);>Matthew Ewend</span> – University of North Carolina</p> ### @@@ Simon Khagi, MD – University of North Carolina Chapel Hill ### 613946###Author###Associate Oncology Service Line Director###University of North Carolina Chapel Hill###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=613946 href=javascript: void(0);>Simon Khagi, MD</span> – University of North Carolina Chapel Hill</p> ### @@@ Darren Lovick – Advent Health ### 1713426###Author######Advent Health###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1713426 href=javascript: void(0);>Darren Lovick</span> – Advent Health</p> ### @@@ Jana L. Portnow, MD – City of Hope ### 612182###Author###Clinical Professor###City of Hope###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=612182 href=javascript: void(0);>Jana L. Portnow, MD</span> – City of Hope</p> ### @@@ Lyndon Kim, MD – Mount Sinai Hospital ### 1712109###Author######Mount Sinai Hospital###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1712109 href=javascript: void(0);>Lyndon Kim, MD</span> – Mount Sinai Hospital</p> ### @@@ William Loudon – St. Joseph's Hospital ### 1713433###Author######St. Joseph's Hospital###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1713433 href=javascript: void(0);>William Loudon</span> – St. Joseph's Hospital</p> ### @@@ Nina Martinez, MD – Jefferson University ### 816220###Author###Assistant Professor of Neurology###Jefferson University###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=816220 href=javascript: void(0);>Nina Martinez, MD</span> – Jefferson University</p> ### @@@ Reid C. Thompson, M.D. – Vanderbilt University Medical Center ### 818880###Author###Director, Neurosurgical Oncology###Vanderbilt University Medical Center###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=818880 href=javascript: void(0);>Reid C. Thompson, M.D.</span> – Vanderbilt University Medical Center</p> ### @@@ David Avigan – Beth Israel Deaconess Medical Center ### 1713437###Author######Beth Israel Deaconess Medical Center###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1713437 href=javascript: void(0);>David Avigan</span> – Beth Israel Deaconess Medical Center</p> ### @@@ Karen L. Fink, MD, PhD – Baylor University Medical Center ### 611347###Author###Neuro-Oncologist###Baylor University Medical Center###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=611347 href=javascript: void(0);>Karen L. Fink, MD, PhD</span> – Baylor University Medical Center</p> ### @@@ Francois Geoffroy – Illinois Cancer Care ### 992070###Author######Illinois Cancer Care###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=992070 href=javascript: void(0);>Francois Geoffroy</span> – Illinois Cancer Care</p> ### @@@ Pierre Giglio, M.D. – Ohio State University Comprehensive Cancer Center ### 611341###Author###Associate Professor###Ohio State University Comprehensive Cancer Center###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=611341 href=javascript: void(0);>Pierre Giglio, M.D.</span> – Ohio State University Comprehensive Cancer Center</p> ### @@@ Oleg Gligich – Mount Sinai Medical Center ### 1713448###Author######Mount Sinai Medical Center###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1713448 href=javascript: void(0);>Oleg Gligich</span> – Mount Sinai Medical Center</p> ### @@@ Dietmar Krex, M.D. – Department of Neurosurgery, University of Dresden ### 611403###Author###Senior Physician###Department of Neurosurgery, University of Dresden###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=611403 href=javascript: void(0);>Dietmar Krex, M.D.</span> – Department of Neurosurgery, University of Dresden</p> ### @@@ Scott M Lindhorst, M.D. – Medical University of South Carolina ### 614272###Author###Associate Professor###Medical University of South Carolina###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=614272 href=javascript: void(0);>Scott M Lindhorst, M.D.</span> – Medical University of South Carolina</p> ### @@@ Jose Lutzky – University of Miami ### 1713610###Author######University of Miami###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1713610 href=javascript: void(0);>Jose Lutzky</span> – University of Miami</p> ### @@@ Hans-Joerg Meisel – Bergmannstrost ### 1713613###Author######Bergmannstrost###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1713613 href=javascript: void(0);>Hans-Joerg Meisel</span> – Bergmannstrost</p> ### @@@ Minou Nadji-Ohl – Klinikum der Landeshauptstadt Stuttgart ### 1713616###Author######Klinikum der Landeshauptstadt Stuttgart###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1713616 href=javascript: void(0);>Minou Nadji-Ohl</span> – Klinikum der Landeshauptstadt Stuttgart</p> ### @@@ Lhagva Sanchin – Bergmannstrost ### 1713619###Author######Bergmannstrost###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1713619 href=javascript: void(0);>Lhagva Sanchin</span> – Bergmannstrost</p> ### @@@ Andrew E. Sloan, MD MBA FACS – Department of Pathology and Department of Neurosurgery, Case Western Reserve University and University Hospitals Cleveland Medical Center; Seidman Cancer Center and Case Comprehensive Cancer Center ### 613033###Author###Professor & Vice Chairman, Department of Neurosurgery###Department of Pathology and Department of Neurosurgery, Case Western Reserve University and University Hospitals Cleveland Medical Center; Seidman Cancer Center and Case Comprehensive Cancer Center###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=613033 href=javascript: void(0);>Andrew E. Sloan, MD MBA FACS</span> – Department of Pathology and Department of Neurosurgery, Case Western Reserve University and University Hospitals Cleveland Medical Center; Seidman Cancer Center and Case Comprehensive Cancer Center</p> ### @@@ Marnix Bosch – Northwest Biotherapeutics, Inc ### 1087532###Author######Northwest Biotherapeutics, Inc###<p style='margin-bottom:5px;'>Author: <span class=biopopup data-url=ajaxcalls/aabiographyinfo.asp?hid=1087532 href=javascript: void(0);>Marnix Bosch</span> – Northwest Biotherapeutics, Inc</p> ### <div class='visible-xs col-xs-12 list-tools-wrap presIcons' style='margin-top:10px;'></div></li><li class="list-group-item loadbyurl preswithfee " data-presid="1137446" data-url="ajaxcalls/PresentationInfo.asp?efp=WlNFRU1UUloxNzM2NA&PresentationID=1137446&rnd=0.7747401" data-buildcode="P" ><div class="col-xs-12 col-sm-3 prestime tipsytip" title=''>8:30 AM – 8:40 AM <small>ET</small></div><div class="col-xs-10 col-sm-8 col-xs-10 prestitle"><span style="color:#5a5a5a">PATH-11 - The longitudinal evolutionary trajectory of oligodendroglioma is driven by treatment-associated genetic alterations<div class='presBadges' style='margin-bottom:0px;'><img class='tipsytip' title='This session will have CME.' src='https://www.conferenceharvester.com/uploads/harvester/presentations/Badges/NKWSJRBQ-Badge7505.png'; width='25' style='mix-blend-mode: darken;'></div></span><span id="test" style="display:none;"></span><br /><small class='location text-supermuted'>Location: East Hall</small><div style='margin-top:5px; font-size:12px; white-space: pre-line'><div class='SessionModerators'><p style='margin-bottom:5px;'>Plenary Abstract Presenter: <span class='loadbyurl popup-link' data-url=ajaxcalls/PresenterInfo.asp?HPRID=818632 href=javascript: void(0);>Frederick S. Varn, PhD</span> – The Jackson Laboratory</p></div></div>
</div>
The issue appears related to OTC stocks.
Form S-3 just filed.
According to a search of NWBO's OTC profile page through the WayBack Machine, Bruce Poignant was been listed as a consultant as early as May 21, 2017.
Section 951 of the Dodd–Frank Act requires public companies to conduct a non-binding shareholder vote on executive compensation at least once every three years. 15 U.S.C. § 78n–1.
Try these steps:
1. Go to the link: www.meetingcenter.io/227204437
2. Accept to the site terms and conditions.
3. Select "I am a guest"
4. Input your Title, First Name, Last Name and Email, and hit Enter.
You are now registered, the Broadcast bar should appear at the time of the meeting.
Today is February 18, 2020.
Dave Innes
804-513-4758 dinnes@nwbio.com
You are wrong. The 5-16-2019 incorrect disclosure was also electronically signed, and can be viewed at:
https://backend.otcmarkets.com/otcapi/company/financial-report/220637/content
This morning, I received the below email from Dinnes@nwbio.com. Is this legitimate? Has anyone else received a similar email. Please note, the text below is a direct cut-and-paste from the email I received, and has some punctuation errors.
"Would you have any time to speak on the phone in the next few days? As you may have read ,I have been hired by Northwest Biotherapeutics as Vice President of Investor Relations and Les has asked me to reach out to as many shareholders as possible. If you have any availability please let me know. I can be reached just about any time at 804 513 4758.
Look forward to hearing from you
Best
Dave Innes"
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6
Quote:
"Results
For the intent-to-treat (ITT) population (n?=?331), median OS (mOS) was 23.1 months from surgery. Because of the cross-over trial design, nearly 90% of the ITT population received DCVax-L. For patients with methylated MGMT (n?=?131), mOS was 34.7 months from surgery, with a 3-year survival of 46.4%. As of this analysis, 223 patients are?≥?30 months past their surgery date; 67 of these (30.0%) have lived?≥?30 months and have a Kaplan-Meier (KM)-derived mOS of 46.5 months. 182 patients are?≥?36 months past surgery; 44 of these (24.2%) have lived?≥?36 months and have a KM-derived mOS of 88.2 months. A population of extended survivors (n?=?100) with mOS of 40.5 months, not explained by known prognostic factors, will be analyzed further. Only 2.1% of ITT patients (n?=?7) had a grade 3 or 4 adverse event that was deemed at least possibly related to the vaccine. Overall adverse events with DCVax were comparable to standard therapy alone."
260,000,000 new common shares after conversion from preferred?
From p. 5 of the report:
During statistical analyses, aDCs from 3 patients showed an
aberrant pattern of cytokine production compared with those of
aDCs from the majority of patients. The aDCs from these patients
produced high levels of IL8 and IL6 but low levels of TNFa, and
results from these patients consistently emerged as statistical
outliers. The first outlier patient was a 51-year-old male melanoma
patient from the 6-million aDC treatment group. He had five
lesions and underwent one round of treatment previously. He
received three injections, had SD at week 8, and died approximately
9 months after the first injection. The second was a 59-yearold
female breast cancer patient in the 6-million aDC treatment
group. She had three lesions and had undergone eight rounds of
treatment previously. She received three injections and died
approximately 1 month after the first injection. The third was a
52-year-old male lung cancer patient in the 15-million aDC
treatment group. He had three lesions and underwent five rounds
of treatment previously. He received three injections, had PD at
week 8, and died approximately 3.5 months after the first injection.
All three patients had a heavy burden of disease and an
extremely poor prognosis. The three patients did not have other
known prominent features that separated them from the rest of
the trial subjects. An exploratory analysis of the aDCs from one of
the patients using immunophenotyping suggested that the purified
monocytes may have failed to completely transform into
aDCs. Thus, we attributed the aberrant cytokine pattern to incomplete
monocyte-to-DC differentiation that was not detectable
initially based on the aDC release criteria used in the trial. In the
subsequent analyses whereDCquality was compared with patient
outcomes, the outlier patient data were excluded.
Get over yourself Flipper44. Its not difficult to understand the slide presentation in conjunction with the report, the links to which appear right next to each other on the Company's Home page under the August 29 entry of the "Most Recent Presentations." Its obvious that the presentation and the report should be read together.
Wrong. The one patient that could not be evaluated was not included in the clinical report. Further, the three patients with "poorly differentiated DCs" were not included within the Table 3 of the clinical report which lists the same 36 patients as listed in the "Long Tail" slide from the presentation.
It was a slide presentation which you did not attend. The slide presentation was posted on the company website with the clinical report. The slide presentation is not difficult to interpret along with the referenced report. There is no need for a footnote.
There are no mistakes in the slide presentation.
Page 18: States that 140 treatments were administered to 40 patients in the Phase I trial. According to the accompanying report, "In total, 39 of the 40 enrolled patients were evaluable. See http://clincancerres.aacrjournals.org/content/clincanres/early/2018/06/18/1078-0432.CCR-17-2707.full.pdf
Page 13: Shows 39 patients in 4 categories ... Alive, Poorly differentiated DCs, Deceased and Lost to follow up.
Page 17: Shows 36 patients in 3 categories ... Alive, Deceased and Lost to follow up.
Thus, the slide at page 17 does not include the 3 patients with "Poorly differentiated DCs"
Your comment assumes the Preferred shares were sold to raise cash for NWBO as opposed to rewarding insiders with cheap shares.
Major Bankz ... when do you graduate from High School? I bet you are looking forward to starting community college.
LP can release some of her 109,849,800 shares back to the company.
Hasn't NWBO already missed the 15 calendar day extension deadline for the filing of of its 10k?
Just download the document as a .pdf and you can cut and paste all you want.
Wrong. That 100 share trade was a form T trade.
I've had an unfilled purchase order on the ASK for almost an hour, 2,500 shares at 0.274. What's up with that?
What about the June 27, 2017 meeting? Here are the links and content:
https://neuromedia.mcgill.ca/mnibooking/view_entry.php?id=124803&day=8&month=2&year=2017
Neuro Media Services - Audio Visual
Help
Admin
Report
Search:
Unknown user
User list
DCVax SIV
Description: Name: Lisa Nezvitsky
Department Head: Dr. Genge
Meeting Name: DCVax SIV
Telephone:514-398-2801
Room: North Wing Pavilion - Room NW123
Start Time: 13:15:00 - Wednesday 08 February 2017
Duration: 3.25 hours
End Time: 16:30:00 - Wednesday 08 February 2017
AV Support?: Room Only!
Entry Made By: tony
Last Updated: 15:10:42 - Tuesday 31 January 2017
Repeat Type: None
https://neuromedia.mcgill.ca/mnibooking/view_entry.php?id=128029
Neuro Media Services - Audio Visual
Help
Admin
Report
Search:
Unknown user
User list
DCVax Monitor
Description: ame: Lisa Nezvitsky
Department Head: Dr. Genge
Meeting Name: DCVax Monitor
Telephone:514-398-2801
Room: Penfield Pavilion - Rasmussen Reading Room
Start Time: 08:30:00 - Tuesday 27 June 2017
Duration: 7.5 hours
End Time: 16:00:00 - Tuesday 27 June 2017
AV Support?: Room Only!
Entry Made By: tony
Last Updated: 15:54:21 - Thursday 11 May 2017
Repeat Type: None
http://webcache.googleusercontent.com/search?q=cache:haN96fvQdmQJ:neuromedia.mcgill.ca/mnibooking/view_entry.php%3Fid%3D131935%26day%3D17%26month%3D10%26year%3D2017+&cd=6&hl=en&ct=clnk&gl=us
Neuro Media Services - Audio Visual
Help
Admin
Report
Search:
Unknown user
User list
DCVax Monitor
Description:
Name: Lisa Nezvitsky
Department Head: Dr. Genge
Meeting Name: DCVax Monitor
Telephone:514-398-2801
Room: Penfield Pavilion - Closed due to renovations till July 19 inclus
Start Time: 08:30:00 - Tuesday 17 October 2017
Duration: 7.5 hours
End Time: 16:00:00 - Tuesday 17 October 2017
AV Support?: Room Only!
Entry Made By: tony
Last Updated: 15:53:19 - Thursday 06 July 2017
Repeat Type: None
A meeting was also conducted on June 27, 2017.
DCVax Monitor
Description: ame: Lisa Nezvitsky
Department Head: Dr. Genge
Meeting Name: DCVax Monitor
Telephone:514-398-2801
Room: Penfield Pavilion - Rasmussen Reading Room
Start Time: 08:30:00 - Tuesday 27 June 2017
Duration: 7.5 hours
End Time: 16:00:00 - Tuesday 27 June 2017
AV Support?: Room Only!
Entry Made By: tony
Last Updated: 15:54:21 - Thursday 11 May 2017
Repeat Type: None
The 8k was not a section 8.01 disclosure. It was a Regulation FD disclosure.
See these links:
https://www.sec.gov/fast-answers/answers-regfdhtm.html
https://www.sec.gov/rules/final/33-7881.htm
It is not the law. Research Regulation FD disclosures for the answer.
You need to do a little more research on Regulation FD disclosures. The 8k was a Regulation FD disclosure.
New documents in the Chardan case are available on Pacer.
My trading platforms show no bid or ask data for NWBO. Same at Yahoo Finance. Any thoughts?